Back

Design and baseline data of AZURE-LDL, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVD

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Clinical impact of lipid‑lowering strategies Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Michael Koren

ENCORE Research Group, Jacksonville (United States of America)

5 More presentations in this session

Presentation thumbnail
Efficacy and safety of recaticimab in lowering atherogenic lipids in patients with and without coronary artery disease: a patient-level pooled analysis
Professor C. Li (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
Comparative efficacy of APOC3- and ANGPTL3-targeted therapies in severe hypertriglyceridemia: a systematic review and network meta-analysis
Doctor G. Caldeira Gaelzer (Curitiba, BR)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) levels in patients hospitalized for acute coronary syndrome according to prior statin therapy.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides Video
Presentation thumbnail
Treatment with PCSK9 inhibitors reduces the expression of scavenger receptors CD16, CD36 and CD45 in patients with stable coronary artery disease and elevated Lp(a) levels
Doctor S. Ugovsek (Ljubljana, SI)
Abstract Slides Video
Presentation thumbnail
LDL-c levels and clinical outcomes in acute myocardial infarction patients with prior ischemic stroke
Professor K. Chen (Tianjin, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical impact of lipid‑lowering strategies

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia
29 August 2026
thumbnail
Congress Presentation
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis
1 September 2025
thumbnail
Congress Presentation
Efficacy of enlicitide, an oral PCSK9 inhibitor, across baseline Lp(a) strata in an analysis of two phase 3 trials
28 August 2026
thumbnail
Congress Presentation
AZD0780, a novel, oral PCSK9 inhibitor with properties allowing for broad use, food-intake independency and co-administration with other lipid lowering therapies
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources